Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM2902 in HER2-expressing advanced solid tumors
NCT05076591Phase 1Suspended
- Sponsor
- ImmuneOnco
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM2902 in solid tumor (advanced stage), breast cancer, gastric cancer (GC) and 2 more, sponsored by ImmuneOnco. Primary endpoints: Dose-Limiting Toxicity at 48 weeks, Maximum Tolerated Dose at 48 weeks and 2 more. Started Jun 2022; status: suspended.
02
Drugs
IMM2902
03
Conditions
solid tumor (advanced stage)breast cancergastric cancer (GC)esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05076591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076591.